Renal Failure Related to Drugs and Disease

  • Scott Wadler
  • Janice P. Dutcher

Abstract

Renal failure in the cancer patient generally falls in one of three categories: tubulointerstitial disease, acute glomerulonephritis, and acute obstructive uropathy (see Table 1). Diagnosis and management of the first two are discussed in this chapter; the third is discussed in Chapter 21.

Keywords

Nephrotic Syndrome Renal Insufficiency Minimal Change Disease Fanconi Syndrome Crescentic Glomerulonephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bitran JD, Desser RK, Billings AA, et al: Acute nephrotoxicity following cis-diamminedichloroplatinum. Cancer 49: 1784–1788, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Loehrer PJ, Einhorn LH: Cisplatin. Ann Intern Med 100: 704–713, 1984.CrossRefGoogle Scholar
  3. 3.
    Bruntsch U, Groos G, Tigges FJ, Gallmeier WM: Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients. Eur J Cancer Clin Oncol 20: 905–909, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Cantrell JE, Phillips TM, Schein PS: Carcinoma-associated hemolytic-uremic syndrome: A complication of mitomycin-C chemotherapy. J Clin Oncol 3: 723–734, 1985.PubMedGoogle Scholar
  5. 5.
    Jackson AM, Rose BD, Graff LG, et al: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101: 41–44, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Kressel BR, Ryan KP, Duong AT, et al: Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 48: 1738–1745, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76: 47–56, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Pascal RR: Renal manifestations of extrarenal neoplasms. Hum Pathol 2: 7–15, 1971.Google Scholar
  9. 9.
    Banks RA, Kingswood JC, Slade R, et al: Glomerulonephritis, non-Hodgkin’s lymphoma, and leucocytoclastic vasculitis. Am J Nephrol 4: 114–117, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    Biava CG, Gonwa TA, Naughton JL, Hopper J: Crescentic glomerulonephritis associated with non-renal malignancies. Am J Nephrol 4: 208–214, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    Bichel J, Bjorn JK: Nephrotic syndrome and Hodgkin’s disease. Lancet 2: 1425–1426, 1971.PubMedCrossRefGoogle Scholar
  12. 12.
    Eagan JW: Glomerulopathies of neoplasia. Kidney Int 11: 297–306, 1977.CrossRefGoogle Scholar
  13. 13.
    Lee JC, Yamauchi H, Hopper J: The association of cancer and the nephrotic syndrome. Ann Intern Med 64: 41–51, 1966.PubMedCrossRefGoogle Scholar
  14. 14.
    Petzel RA, Brown DC, Staley NA, et al: Crescentic glomerulonephritis and renal failure associated with malignant lymphoma. Am J Clin Oncol 71: 728–732, 1979.Google Scholar
  15. 15.
    Plager J, Stutzman L: Acute nephrotic syndrome as a manifestation of active Hodgkin’s disease: Report of four cases and review of the literature. Am J Med 50: 56–66, 1971.PubMedCrossRefGoogle Scholar
  16. 16.
    Dobbs DJ, Striker LMM, Mignon F, Striker G: Glomerular lesions in lymphomas and leukemias. Am J Med 80: 63–69, 1980.CrossRefGoogle Scholar
  17. 17.
    Glicklich D, Sung MW, Frey M: Renal failure due to lymphomatous infiltration of the kidneys. Cancer 58: 748–753. 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    DeFronzo RA, Cooke CR, Wright JR, Humphrey RL: Renal function in patients with multiple myeloma. Medicine (Baltimore) 57: 151–166, 1978.Google Scholar
  19. 19.
    Solomon A: Clinical implications of monoclonal light chains. Semin Oncol 13: 341–349, 1986.PubMedGoogle Scholar
  20. 20.
    Tubbs RR, Gephardt GN, McMahon JT, Hall PM, Valenzuela R, Vidt DG: Light chain nephropathy. Am J Med 71: 263–269, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Wochner RD, Strober W, Waldman TA: The role of the kidney in the catabolism of Bence-Jones proteins and immunoglobulin fragments. J Exp Med 126: 207–221, 1967.PubMedCrossRefGoogle Scholar
  22. 22.
    Farhangi M, Merlini G: The clinical implications of monoclonal immunoglobulins. Semin Oncol 13: 366–379, 1986.PubMedGoogle Scholar
  23. 23.
    Muggia FM, Heinemann HO, Farhangi M, Osserman EF: Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med 47: 351–366, 1969.PubMedCrossRefGoogle Scholar
  24. 24.
    Pruzanski W, Platts ME: Serum and urinary proteins, lysozyme (muramidase), and renal dysfunction in mono-and myelocytic leukemia. J Clin Invest 49: 1694–1708, 1970.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Scott Wadler
    • 1
  • Janice P. Dutcher
    • 2
    • 3
  1. 1.Department of OncologyAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA
  2. 2.Department of Medicine, Division of Medical OncologyAlbert Eistein College of MedicineBronxUSA
  3. 3.Department of OncologyMontefiore Medical CenterBronxUSA

Personalised recommendations